Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.40 |
| ▸ | SELE | P16581 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPRA | P18433 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
| ▸ | MAP3K8 | P41279 | 2/20 | 0.37 |
| ▸ | CCNC | P24863 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1116031 | 0.78 | EGLN1 (0.50) | LRRK2 | |
| SCHEMBL5488037 | 0.74 | EGLN2 (0.45) | CHEK1ICAM1SELEPTPN1PTPRA | |
| SCHEMBL1973999 | 0.71 | MAPT (0.42) | SCN9AMAPTKDM4ESMN1; SMN2TDP1 | |
| SCHEMBL27755823 | 0.71 | ADORA2A (0.40) | ADORA2AMAPTKDM4ESMN1; SMN2BACE1 | |
| SCHEMBL967020 | 0.71 | EGLN1 (0.65) | — | |
| SCHEMBL21670013 | 0.70 | EGLN1 (0.52) | CHEK2SCN9AADORA2ALRRK2MAPT | |
| SCHEMBL28570242 | 0.69 | THRA (0.52) | CHEK2SCN9AADORA2ALRRK2KDM4E | |
| SCHEMBL28556240 | 0.69 | THRA (0.51) | CHEK2SCN9AADORA2ALRRK2MAPT | |
| SCHEMBL27861661 | 0.67 | PARP10 (0.41) | ICAM1SELEADORA2AVCAM1PARP10 | |
| SCHEMBL28993794 | 0.67 | EGLN2 (0.50) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070292433-A1 | Compounds and methods for treatment of chemotherapy-induced anemia | FIBROGEN, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070292433-A1 | Compounds and methods for treatment of chemotherapy-induced anemia | EPOR, MCL1, HIF1AN | CHEK1 1795/4885ICAM1 3047/4885SELE 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.